- Home
- VRAX vs BCLI Comparison
VRAX vs BCLI Comparison
Compare VRAX & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- BCLI
- Stock Information
- Founded
- VRAX 2013
- BCLI 2000
- Country
- VRAX United Kingdom
- BCLI United States
- Employees
- VRAX N/A
- BCLI N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VRAX Health Care
- BCLI Health Care
- Exchange
- VRAX Nasdaq
- BCLI Nasdaq
- Market Cap
- VRAX 5.9M
- BCLI 6.4M
- IPO Year
- VRAX 2022
- BCLI N/A
- Fundamental
- Price
- VRAX $1.09
- BCLI $0.92
- Analyst Decision
- VRAX Strong Buy
- BCLI Strong Buy
- Analyst Count
- VRAX 1
- BCLI 1
- Target Price
- VRAX $3.00
- BCLI $30.00
- AVG Volume (30 Days)
- VRAX 300.7K
- BCLI 366.6K
- Earning Date
- VRAX 02-05-2025
- BCLI 05-13-2025
- Dividend Yield
- VRAX N/A
- BCLI N/A
- EPS Growth
- VRAX N/A
- BCLI N/A
- EPS
- VRAX N/A
- BCLI N/A
- Revenue
- VRAX $84,872.00
- BCLI N/A
- Revenue This Year
- VRAX $5,169.18
- BCLI N/A
- Revenue Next Year
- VRAX $66.97
- BCLI N/A
- P/E Ratio
- VRAX N/A
- BCLI N/A
- Revenue Growth
- VRAX 7.03
- BCLI N/A
- 52 Week Low
- VRAX $0.60
- BCLI $0.72
- 52 Week High
- VRAX $9.00
- BCLI $10.05
- Technical
- Relative Strength Index (RSI)
- VRAX 48.47
- BCLI 35.85
- Support Level
- VRAX $0.91
- BCLI $1.12
- Resistance Level
- VRAX $1.09
- BCLI $0.82
- Average True Range (ATR)
- VRAX 0.11
- BCLI 0.12
- MACD
- VRAX 0.03
- BCLI 0.01
- Stochastic Oscillator
- VRAX 51.92
- BCLI 36.36
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.